Array BioPharma Inc. (ARRY)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.60+0.16 (+4.65%)
At close: 4:00 PM EDT

3.60 0.00 (0.00%)
After hours: 4:24 PM EDT

People also watch:
ARQLEXELCLDXRIGLARIA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open3.58
Prev Close3.44
Bid3.55 x 3000
Ask3.60 x 600
Day's Range3.50 - 3.75
52wk Range2.38 - 6.01
1y Target EstN/A
Market Cap522.08M
P/E Ratio (ttm)-5.54
Beta1.25
Volume3,105,542
Avg Vol (3m)2,137,110
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • 24/7 Wall St.5 hours ago

    Array BioPharma Continues Its Silent Rally With Mid-Stage Trial Win

    Shares of Array BioPharma saw a handy gain in Tuesdays session following the announcement of mid-stage results from its cardiomyopathy trial.

  • PR Newswire9 hours ago

    Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress

    BOULDER, Colo., Aug. 30, 2016 /PRNewswire/ -- Array BioPharma (ARRY) announced today results from a Phase 2 study of ARRY-797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy (LMNA-related DCM), a rare, degenerative cardiovascular disease caused by mutations in the LMNA gene and characterized by poor prognosis.  The trial results were presented at the European Society of Cardiology Congress 2016 in Rome, Italy. The results demonstrated an absolute mean change from baseline of 69 meters on the six-minute walk test (6MWT) at week 12, the study's primary endpoint (baseline 6MWT ranged from 246 to 412 meters).  This magnitude of improvement exceeded historical benchmarks for 6MWT that have served as the basis for recent approvals of other drugs in other rare diseases.  ARRY-797 administration also resulted in sustained improvements in N-terminal pro-brain natriuretic peptide (NT-proBNP), functional capacity and cardiac function through 48 weeks in LMNA-related DCM patients.

  • TheStreet.comyesterday

    Array BioPharma (ARRY) Stock Advances, Price Target Raised at Jefferies

    Jefferies upped its price target on Array BioPharma (ARRY) to $7 earlier today.